Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Madroszyk

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2025
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci studyM Wislez, C Mascaux, J Cadranel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2023
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trialJ Remon, B Besse, S Ponce Aix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2023
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerH Borghaei, F de Marinis, D Dumoulin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2023
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1B Besse, E Felip, R Garcia Campelo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 14, 2026
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trialG Zalcman, A Madroszyk, E Guenzi, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2025
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci studyM Wislez, C Mascaux, J Cadranel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2023
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trialJ Remon, B Besse, S Ponce Aix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2023
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerH Borghaei, F de Marinis, D Dumoulin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2023
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1B Besse, E Felip, R Garcia Campelo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 14, 2026
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trialG Zalcman, A Madroszyk, E Guenzi, et al.
Pageof 2